SPOTLIGHT: Wyeth R&D chief exits with kudos for success


The blogsters at In Vivo have weighed in on the news that Wyeth R&D chief Bob Ruffolo is retiring. He may have been tough to get along with, but the blog gives Ruffolo credit for some significant achievements in new drug approvals at a time most of the industry has been experiencing a long, dry spell. Ruffolo had early on noted the rising number of mid-stage trials that were failing, noting that the only sensible response was to increase the number of experimental therapies in the pipeline. All eyes now turn to the new R&F chief, Mikael Dolsten. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.